Add BrightSurf on Google Email

Nano-immunotherapy developed to improve lung cancer treatment

Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...

SourceBrigham and Women's Hospital·JournalScience Advances·TypeExperimental study·DateJun 14, 2024

Promising role of antidiabetic drug in cancer control

Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.

SourceFlinders University·JournalCancers·TypeExperimental study·DateJun 11, 2024

Targeting “monster cancer cells” could reduce recurrence rates after cancer therapy

Researchers at MUSC Hollings Cancer Center discover polyploid giant cancer cells can lead to disease recurrence after chemotherapy or radiotherapy. They found that targeting these 'monster cells' could prevent tumor relapse, and potential therapies like tamoxifen and statins may also be effective.

SourceMedical University of South Carolina·JournalJournal of Biological Chemistry·TypeExperimental study·DateMay 28, 2024

Exercise bouts could improve efficacy of cancer drug

A study found that moderate-to-vigorous exercise bouts increased natural killer cells' ability to kill cancer cells and made them more susceptible to antibody therapy. This could hold promise for improving treatment outcomes for some forms of chronic lymphocytic leukemia. Further research is needed to confirm these findings.

SourceUniversity of Birmingham·JournalBrain Behavior and Immunity·TypeExperimental study·DateMay 21, 2024

Hyperspectral dark-field microscopy for rapid and accurate identification of cancerous tissues

Researchers have developed a new imaging technique that rapidly and accurately identifies cancerous tissues in breast samples. The method uses machine learning algorithms trained on hyperspectral dark-field microscopy data to pinpoint regions of invasive ductal carcinoma and invasive mucinous carcinoma.

SourceSPIE--International Society for Optics and Photonics·JournalJournal of Biomedical Optics·DateMay 8, 2024

In a first, researchers generate a direct measurement of the interaction between immune cells and cancer cells from a patient’s biopsy

A team of researchers at Bar-Ilan University has developed a groundbreaking technology that enables direct measurement of the interaction between immune cells and cancer cells from a patient's biopsy. This innovation provides crucial insights into the patient's immune response, enabling tailored cancer treatment decisions.

SourceBar-Ilan University·JournalRNA·DateMay 6, 2024

Testing for residual cancer cells before blood cell transplant therapy is important and practical, new study finds

A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.

SourceVirginia Tech·JournalJAMA Oncology·TypeData/statistical analysis·DateMay 2, 2024

World-first microscopic stiffness probe could revolutionise early cancer diagnosis

Researchers at the University of Nottingham have created a world-first device that can image individual cells' stiffness, potentially catching cancer earlier. The technology uses Brillouin scattering to detect stiffness down to billionths of a meter and could replace traditional biopsies with non-invasive, single-cell imaging.

SourceUniversity of Nottingham·JournalCommunications Biology·TypeExperimental study·DateApr 15, 2024

Targeted liver cancer treatment kills cancer cells and cuts chemo side effects

Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.

SourceUniversity of South Australia·JournalInternational Journal of Pharmaceutics·TypeExperimental study·DateApr 14, 2024

‘Exhausted’ immune cells in healthy women could be target for breast cancer prevention

A study published in Nature Genetics reveals early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations, suggesting a potential target for breast cancer prevention. The researchers created the world's largest catalogue of human breast cells, which may lead to the use of existing immunotherapy drugs as an early intervention.

SourceUniversity of Cambridge·JournalNature Genetics·DateMar 28, 2024

Breast cancer patients can safely avoid extensive removal of lymph nodes if they respond well to primary systemic treatment

A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.

An immunotherapy to overcome resistant leukemia

Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.

SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024

Researchers uncover a potential genetic marker associated with better survival outcomes in patients with head and neck cancer

A study published in Cancer Research Communications reveals a potential genetic marker associated with better survival outcomes in patients with head and neck cancer. The researchers found that the presence of a specific genetic variant and higher expression of the GAN gene product gigaxonin may contribute to improved survival rates.

SourceUniversity of California - Los Angeles Health Sciences·JournalCancer Research Communications·DateFeb 29, 2024

Nanocarrier with escape reflex

A new nanocarrier has been developed that can selectively release drugs in cancer cells through controlled endosomal escape. The approach exploits the unique enzymatic activity of cancer cells, allowing for targeted delivery and reduced harm to healthy cells.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateFeb 28, 2024

Outsmarting chemo-resistant ovarian cancer

Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.

SourceNorthwestern University·JournalAdvanced Science·TypeExperimental study·DateFeb 21, 2024

Deciphering cell-to-cell conversations: AI predicts anti-cancer immunotherapy response

A recent study used AI trained on cell-to-cell communication networks to predict drug responsiveness in immunotherapy for cancer. The model demonstrated high accuracy in analyzing samples from 700 patients with four types of cancer, identifying key communication pathways related to responsiveness and resistance.

Epigenetic combination therapy could overcome treatment resistance in epithelioid sarcomas and rhabdoid tumors

Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.

SourceMemorial Sloan Kettering Cancer Center·JournalCancer Discovery·TypeExperimental study·DateFeb 5, 2024

New technology makes cancer easier for immune system to find and destroy

A new CRISPR-based technology, TRED-I, has been developed to increase visibility of cancer cells to the immune system by augmenting MHC class I molecules. This technology has shown promising results in animal cancer models, reducing tumor sizes and enhancing treatment efficacy when used with existing immunotherapy.

SourceHokkaido University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJan 29, 2024